Stereotactic Radiation Preserves Quality of Life Over Hippocampal-Avoidance Whole Brain Radiation in Patients with 5 to 20 Brain Metastases

Highlights

A phase 3 randomized clinical trial involving 196 patients has demonstrated that stereotactic radiation (SR) significantly improves patient-reported symptom severity compared to hippocampal-avoidance whole brain radiation (HA-WBRT) for those with 5 to 20 brain metastases.

Patients receiving SR experienced a mean improvement in symptom scores (-0.32), whereas those receiving HA-WBRT experienced a worsening of symptoms (+0.74), resulting in a clinically meaningful difference of -1.06.

The study highlights a lower incidence of treatment-related fatigue in the SR group (28%) compared to the HA-WBRT group (44%), reinforcing the value of focal therapy even in cases of higher intracranial tumor volume.

Background: The Evolution of Brain Metastasis Management

Brain metastases represent a significant clinical challenge in oncology, occurring in approximately 20% to 40% of all cancer patients. Historically, whole brain radiation therapy (WBRT) was the standard of care for patients with multiple lesions. However, the neurocognitive decline and decrement in quality of life associated with WBRT led to the development of more targeted approaches. Stereotactic radiosurgery (SRS) or stereotactic radiation (SR) became the preferred option for patients with limited disease (typically 1 to 4 metastases), as it offers excellent local control while sparing healthy brain tissue.

As imaging technology and delivery systems improved, the boundaries for SR expanded. Clinicians began treating patients with 5 to 20 metastases with SR, but level 1 evidence comparing this to modern WBRT techniques was lacking. Hippocampal-avoidance WBRT (HA-WBRT) was developed to mitigate the cognitive risks of traditional WBRT by sparing the regenerative stem cells in the hippocampus. Despite this advancement, the question remained: for patients with 5 to 20 metastases, is focal treatment still superior to the most advanced form of whole-brain treatment?

Study Design and Methodology

This phase 3, open-label, randomized clinical trial was conducted across four major United States-based centers. The study enrolled 196 patients between April 2017 and May 2024, with a final follow-up in March 2025. This cohort represented a challenging patient population, with a median of 14 brain metastases per patient (interquartile range, 11-18).

Patient Population and Randomization

Eligible participants included adults with 5 to 20 brain metastases confirmed by contrast-enhanced MRI. Importantly, patients must not have received prior brain-directed radiation. The participants were randomized in a 1:1 ratio to receive either SR targeting only the individual tumors or HA-WBRT, which encompasses the entire brain volume while specifically sparing the hippocampal regions. The mean age of the cohort was 61 years, with a majority being female (66%) and White (90%).

Intervention Protocols

The SR group received targeted radiation to each identifiable lesion. The HA-WBRT group received 30 Gy in 10 fractions with intensity-modulated radiation therapy (IMRT) designed to limit the dose to the bilateral hippocampi. This comparison was designed to test whether the focal nature of SR provided a better symptom profile than the comprehensive but “sparing” approach of HA-WBRT.

Primary and Secondary Endpoints

The primary outcome was the change in the weighted patient-reported symptom severity and interference score over 6 months post-baseline. This was measured using the MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) instrument. The scale ranges from 0 to 10, where a change of 0.98 was pre-defined as clinically meaningful. Secondary endpoints included adverse events, local control, and overall survival.

Key Findings: A Clear Advantage for Stereotactic Radiation

The results of the trial provide strong evidence favoring stereotactic radiation for the management of extensive brain metastases. At the 6-month assessment, 42% of the randomized patients remained evaluable for the primary outcome.

Primary Outcome: MDASI-BT Score Changes

The statistical analysis revealed a stark divergence between the two treatment arms. In the SR group, the weighted composite MDASI-BT score improved from a baseline of 2.69 to 2.37, representing a mean change of -0.32. Conversely, the HA-WBRT group saw their scores rise (worsen) from 2.29 at baseline to 3.03, a mean change of +0.74. The resulting mean difference of -1.06 (95% CI, -1.54 to -0.58; P < .001) exceeded the threshold for clinical significance.

Safety and Adverse Events

Regarding safety, both treatments were relatively well-tolerated with respect to high-grade toxicities. Grade 3-5 adverse events related to treatment occurred in 12% of the SR group and 13% of the HA-WBRT group. However, the profile of lower-grade toxicities favored SR. Most notably, grade 1-3 fatigue was significantly less frequent in the SR group compared to the HA-WBRT group (28% vs 44%). This difference in fatigue likely contributed to the better symptom interference scores reported by patients in the SR arm.

Expert Commentary: Shifting the Paradigm for Extensive Brain Metastases

The findings of this trial, led by Aizer et al., represent a pivotal moment in radiation oncology. For years, the oncology community has debated the “tipping point” where the number of metastases makes WBRT a more logical choice than SR. This study suggests that even with a median of 14 metastases, the focal approach preserves quality of life and reduces the symptom burden more effectively than whole-brain approaches, even when hippocampal avoidance is employed.

Clinical Implications

The data suggest that SR should be considered the preferred treatment for patients with 5 to 20 brain metastases when the goal is to maximize quality of life and minimize treatment-related interference with daily functioning. While HA-WBRT was intended to prevent cognitive decline, it still involves radiating a significant volume of healthy brain tissue, which appears to result in greater fatigue and a higher overall symptom burden than focal treatment.

Study Limitations and Considerations

Despite the clear results, some limitations must be considered. The attrition rate at 6 months (42% completion) reflects the high mortality and morbidity associated with advanced systemic cancer, though this is common in brain metastasis trials. Furthermore, the study was open-label, which can introduce bias in patient-reported outcomes, although the use of a validated instrument like the MDASI-BT helps mitigate this. Future research should continue to evaluate the long-term local control and the potential need for salvage therapies in the SR group, as whole-brain radiation typically provides better protection against new distant brain metastases.

Conclusion

In conclusion, the Aizer et al. randomized clinical trial provides high-level evidence that stereotactic radiation is superior to hippocampal-avoidance whole brain radiation for patients with 5 to 20 brain metastases in terms of symptom severity and daily functioning. These findings support a shift in clinical practice toward focal radiation for patients with higher numbers of intracranial lesions, prioritizing the patient’s quality of life during their treatment journey.

Funding and Clinical Trial Information

This study was supported by various institutional grants and philanthropic funds. ClinicalTrials.gov Identifier: NCT03075072.

References

Aizer AA, Shin KY, Catalano PJ, et al. Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial. JAMA. 2026 Feb 19. doi:10.1001/jama.2026.0076.

Brown PD, Jaeckle K, Ballman KV, et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016;316(4):401-409.

Gondi V, Pugh SL, Tome WA, et al. Preservation of Memory with Hippocampal Avoidance During Whole-Brain Radiotherapy for Brain Metastases: Final Results of Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020;38(10):1019-1029.